GSK 3810109
Alternative Names: 3810109; GSK-3810109; GSK-3810109A; N6LS; VH-3810109; VRC-HIVMAB091-00-AB; Z258‐N6LSLatest Information Update: 26 Mar 2025
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Developer National Institute of Allergy and Infectious Diseases; ViiV Healthcare
- Class Antiretrovirals; Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 12 Mar 2025 Adverse events and efficacy data from a phase IIb EMBRACE trial in HIV infections released byViiV Healthcare
- 28 Apr 2024 No recent reports of development identified for preclinical development in HIV-1-infections(Prevention) in USA (IV, Infusion)
- 28 Apr 2024 No recent reports of development identified for preclinical development in HIV-1-infections(Prevention) in USA (SC, Injection)